Remdesivir (RDV; GS-5734) for the Treatment of Selected Coronavirus (CoV) Infection, Single Patient Protocol

An experimental treatment called Remdesivir was provided on a compassionate-use basis to patients hospitalized with COVID-19, an illness caused by infection with SARS-CoV-2.

Study Type/Phase: Emergency Investigational New Drug
Enrollment Status: Not Recruiting

There is no approved therapy for COVID-19, and current management consists of supportive care, including oxygen support and treatment with antibiotics. In previous experiments, Remdesivir has shown activity against other similar types of viruses, including filoviruses (e.g., Ebola) and coronaviruses (e.g., SARS-CoV and MERS-CoV). Laboratory testing has also shown that Remdesivir has activity against SARS-CoV-2.

Patients were eligible to receive treatment if they had confirmed SARS-CoV-2 infection with an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received Remdesivir for 10 days while admitted to the hospital.

Principal Investigator

Daniel Shin, MD

Sponsor

Gilead Sciences, Inc.

Contact

Kara Turner, Clinical Research Coordinator
Taft Center for Clinical Research
650-962-4562
Kara_Turner@elcaminohealth.org

 

For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.

 

You may also be interested in...

Visitor Screener

Visitor Restrictions

A visitor policy is in effect due to more restrictive measures being taken throughout the Bay Area.
HealthPerks Banner

Sign Up for HealthPerks

It's a free membership program with a monthly newsletter, event registrations, and more.
Find a doctor who will fit you well.

Find a Doctor

Use our directory to find a doctor with an office near our Mountain View or Los Gatos campus.